Background
Slow neurotransmission including DARPP-32 signalling is implicated in substance use disorders (SUDs) by experimental systems but not yet in the human aetiology.
PPP1R12B
, encoding another protein in the DARPP-32 family, hasn't been studied in the brain.
Methods
Brain-regional gene activity was assessed in three different animal models of SUDs for mRNA level alterations. Genetic associations were assessed by meta-analysis of pre-existing dbGaP GWAS datasets for main effects and epistasis with known genetic risks, followed by cell type-specific pathway delineation. Parkinson's disease (PD) was included as a dopamine-related disease control for SUDs.
Findings
In animal models of SUDs, environmentally-altered
PPP1R12B
expression sex-dependently involves motivation-related brain regions. In humans with polysubstance abuse, meta-analysis of pre-existing datasets revealed that
PPP1R12B
and
PPP1R1B
, although expressed in dopamine
vs.
dopamine-recipient neurons, exerted similar interactions with known genetic risks such as
ACTR1B
and
DRD2
in men but with
ADH1B, HGFAC
and
DRD3
in women. These interactions reached genome-wide significances (
P
meta
<10
−20
) for SUDs but not for PD (disease selectivity:
P
= 4.8 × 10
−142
, OR = 6.7 for
PPP1R12B; P
= 8.0 × 10
−8
, OR = 2.1 for
PPP1R1B
).
CADM2
was the common risk in the molecular signalling regardless of gender and cell type.
Interpretation
Gender-dependant slow neurotransmission may convey both genetic and environmental vulnerabilities selectively to SUDs.
Funding
Grants from National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) of U.S.A. and National Natural Science Foundation of China (NSFC).